Patients with dyssynchronous yet viable ventricles are most likely to benefit from cardiac resynchronization therapy combined with defibrillation, concludes the latest analysis of the MADIT CRT trial.

The patients were upgraded to a CRT-D device with the CRT function turned either on (full CRT-D function) or off (ICD capability without biventricular pacing).

Our large CRT study representing a guideline-driven CRT clinical practice observed a consistent improvement in HF symptoms, LV systolic function, and LV reverse remodeling in those older than 80 ...

Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable ...

The results of the BUDAPEST-CRT Upgrade study call for careful monitoring of LV function, percent RV pacing and HF symptoms to identify patients in need for upgrading to CRT," Linde wrote.

AMSTERDAM, the Netherlands—Among patients with heart failure with reduced ejection fraction (HFrEF), a previously implanted pacemaker or ICD, and a significant RV pacing burden, upgrading to a cardiac ...

They compared those who received CRT-D (n = 9,525) with those who received ICD only (n = 1,421), all of whom were fee-for-service Medicare patients at least 65 years of age who underwent ICD ...

The CRT-D, through electrodes placed on pacing leads, paces the two ventricles on the heart at the same time, synchronizing the heart’s electrical and muscle function.

Medtronic CRT devices are now approved to treat patients with atrioventricular (AV) block and left ventricular (LV) systolic dysfunction, reducing heart failure hospitalizations and mortality, and ...

To better understand the long-term effects of CRT on mortality, we analyzed the survival outcomes of patients enrolled at the eight highest-enrolling participating sites.

Eligible heart failure patients with a wide QRS complex spent more time alive after use of a cardiac resynchronization therapy defibrillator (CRT-D) compared with an implantable cardioverter ...

CRT-P recipients had significantly lower medical costs (about $20,000 difference) and cardiac-related medical costs compared with CRT-D recipients at 1 year and 2 years, the researchers wrote.